Philip Morris stock price target raised to $200 from $190 at Goldman Sachs

Goldman Sachs has raised its price target for Philip Morris to $200, maintaining a Conviction Buy rating ahead of Q2 results, citing potential upside surprises driven by strong IQOS momentum, easing ZYN supply constraints, and reduced foreign exchange headwinds. The firm, along with UBS, Citi, Jefferies, and Stifel, highlights PM's impressive 66% gross margins, projected 9% FY2025 revenue growth, and leadership in smoke-free products as key drivers for sustainable long-term profitable growth, despite the stock's significant 73% year-over-year return and current trading above its Fair Value by some analyses.

Analysis

A strong bullish consensus is forming around Philip Morris (PM) among major investment banks ahead of its second-quarter earnings report. Goldman Sachs raised its price target to $200, maintaining a Conviction Buy rating, based on anticipated upside surprises from the continued momentum of its IQOS product and the resolution of supply constraints for its ZYN nicotine pouches, where shipments are now reported to be outpacing consumption. This optimism is echoed by UBS, Citi, Jefferies, and Stifel, which have all recently issued Buy ratings or raised price targets, citing drivers such as expanding smoke-free gross margins, leadership in heated tobacco, and a robust multi-category strategy. The company's fundamentals appear strong, with impressive gross margins of 66% and analysts forecasting 9% revenue growth for fiscal year 2025. This positive outlook is further supported by easing foreign exchange headwinds from a weaker U.S. dollar. However, this bullish sentiment must be weighed against the stock's significant 73% return over the past year and an InvestingPro analysis indicating it is currently trading above its assessed Fair Value, suggesting potential valuation concerns.

Key Decisions for Investors

• Given the strong analyst consensus and fundamental drivers like IQOS growth and ZYN supply recovery, investors could view the upcoming earnings as a potential positive catalyst, warranting a hold or addition to existing positions.
• Potential new investors should weigh the bullish analyst targets against the stock's substantial 73% year-over-year gain and reported overvaluation, which may suggest waiting for a more attractive entry point post-earnings.
• Closely monitor the Q2 results for confirmation of ZYN shipment increases and management's updated FY2025 guidance, particularly regarding the impact of reduced foreign exchange headwinds, as these are the core pillars of the current investment thesis.